Literature DB >> 8557223

Risk of breast cancer in a cohort of infertile women.

M A Rossing1, J R Daling, N S Weiss, D E Moore, S G Self.   

Abstract

The purpose of this study was to assess: (1) the risk of breast cancer associated with use of ovulation-inducing agents (such as clomiphene citrate) as treatment for infertility; and (2) the risk associated with ovulatory abnormalities that result in infertility. We performed a case-cohort study among 3837 women evaluated for infertility at clinics in Seattle, Washington, at some time during 1974-1985. Computer linkage with a population-based tumor registry was used to identify women diagnosed with breast cancer before January 1, 1992. Data regarding infertility testing and treatment were abstracted from the infertility clinic medical records for women who developed breast cancer and a randomly selected subcohort. Twenty-seven women in the cohort developed in situ or invasive breast cancer, in comparison with an expected number of 28.8 cases (standardized incidence ratio, 0.9; 95% confidence interval (CI), ).6-1.4). Infertile women with evidence of an ovulatory abnormality were at a risk of breast cancer similar to that of women whose infertility was believed to be due to other causes. The risk among women who had taken clomiphene was reduced relative to infertile women who had not used this drug (adjusted relative risk, 0.5; 95% CI, 0.2-1.2), but the reduction in risk did not increase with duration of use. The possibility that use of clomiphene as treatment for infertility lowers the risk of breast cancer should be examined in other, larger studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557223     DOI: 10.1006/gyno.1996.0002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Fertility drugs and young-onset breast cancer: results from the Two Sister Study.

Authors:  Chunyuan Fei; Lisa A Deroo; Dale P Sandler; Clarice R Weinberg
Journal:  J Natl Cancer Inst       Date:  2012-07-06       Impact factor: 13.506

2.  Cancer in women after assisted reproductive technology.

Authors:  Barbara Luke; Morton B Brown; Logan G Spector; Stacey A Missmer; Richard E Leach; Melanie Williams; Lori Koch; Yolanda Smith; Judy E Stern; G David Ball; Maria J Schymura
Journal:  Fertil Steril       Date:  2015-08-10       Impact factor: 7.329

3.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

Review 4.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Fertility drugs and the risk of breast and gynecologic cancers.

Authors:  Louise A Brinton; Vikrant V Sahasrabuddhe; Bert Scoccia
Journal:  Semin Reprod Med       Date:  2012-04-27       Impact factor: 1.303

6.  Fertility drug use and mammographic breast density in a mammography screening cohort of premenopausal women.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Mary Beth Terry; Hazel B Nichols; Andrew J Bersch; Diana S M Buist
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

7.  Cancer risk after exposure to treatments for ovulation induction.

Authors:  R Calderon-Margalit; Y Friedlander; R Yanetz; K Kleinhaus; M C Perrin; O Manor; S Harlap; O Paltiel
Journal:  Am J Epidemiol       Date:  2008-11-26       Impact factor: 4.897

8.  Long-term relationship of ovulation-stimulating drugs to breast cancer risk.

Authors:  Louise A Brinton; Bert Scoccia; Kamran S Moghissi; Carolyn L Westhoff; Shelley Niwa; David Ruggieri; Britton Trabert; Emmet J Lamb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04       Impact factor: 4.254

Review 9.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2013-08-13

Review 10.  Circulatory estrogen level protects against breast cancer in obese women.

Authors:  Zsuzsanna Suba
Journal:  Recent Pat Anticancer Drug Discov       Date:  2013-05       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.